Why Is Medpace Holdings (MEDP) Stock Down -22% Today?
Key Takeaways
- Medpace Holdings (MEDP) shares are trading down approximately 22% in pre-market on April 23, 2026, from a prior close of $508.46, implying a pre-market price near $397.
- The primary catalyst is a sub-1.0 net book-to-bill ratio of 0.88x in Q1 2026 — a closely watched metric that signals new bookings fell short of recognized revenue, raising concerns about future backlog growth and revenue sustainability.
- A secondary catalyst is the announced retirement of company President Jesse Geiger, effective May 31, 2026, which triggered a leadership uncertainty discount from investors.
- Despite reporting Q1 revenue of $706.6 million (up 26.5% year-over-year) and EPS of $4.28 — both above consensus — the forward-looking signals overshadowed the headline beat.
- A new securities fraud class-action lawsuit was filed against the company, adding legal overhang.
- Traders are now focused on whether the book-to-bill ratio recovers in Q2 and on the CEO's succession plan for the president role.
Opening Summary
Medpace Holdings, Inc. (MEDP) is a Cincinnati, Ohio-based contract research organization (CRO) that provides outsourced clinical development services — including Phase I through Phase IV trial management, regulatory affairs, data management, and laboratory services — to the pharmaceutical, biotechnology, and medical device industries. After reporting Q1 2026 results after the market close on April 22, shares fell sharply in extended trading and are indicated down approximately 22% in pre-market on April 23, compared to the prior session close of $508.46. The earnings-driven move reflects investor alarm over a net book-to-bill ratio that dropped well below the critical 1.0x threshold, compounded by a leadership departure announcement, even as headline revenue and earnings growth remained strong.
Earnings Results: A Beat That the Market Rejected
Medpace delivered results that, on their surface, looked impressive. Q1 2026 revenue of $706.6 million grew 26.5% year-over-year, beating analyst estimates of roughly $696.3 million. GAAP EPS of $4.28 per diluted share came in significantly above the consensus expectation of $3.74, representing a 14.4% earnings surprise. EBITDA reached $149.4 million, up 25.9% year-over-year, and full-year 2026 revenue guidance of $2.755–$2.855 billion was issued.
However, the market's focus immediately shifted to what these numbers did not show: net income margin compressed from 20.5% to 17.5% year-over-year, and net new business awards of $618.4 million produced a net book-to-bill ratio of just 0.88x — meaning MEDP booked $0.88 of new work for every $1.00 of revenue recognized in the quarter. For a high-growth CRO, analysts typically want this ratio consistently above 1.20x; a reading below 1.0x directly threatens future revenue visibility and backlog expansion.
Book-to-Bill Below 1.0x: The Core Red Flag
The 0.88x net book-to-bill ratio is the central driver of today's selloff. Backlog grew only 2.9% year-over-year to $2.929 billion as of March 31, 2026 — a pace far below Medpace's historical growth trajectory and one that raises questions about whether the company can sustain its current revenue acceleration in 2027 and beyond. This is the second consecutive quarter in which bookings have drawn significant investor concern: in Q4 2025, MEDP reported a book-to-bill of just 1.04x alongside a spike in project cancellations described by management as "the highest in over a year," sending shares down 15.4% at that time. The recurrence of weak bookings data in Q1 2026, rather than the one-quarter blip management had suggested, amplifies the credibility of the demand concern.
Leadership Departure and Legal Overhang
Compounding the booking miss, an 8-K filing disclosed that President Jesse Geiger will retire effective May 31, 2026. While the company stated the departure is not due to any internal disagreement, Geiger's exit follows a series of large insider share sales he conducted over the preceding year — including a 67.88% reduction of his personal position in March 2026 — which investors interpreted as a negative signal at the time. CEO August Troendle will reassume the president role until a successor is named, reintroducing key-person concentration risk at a moment of heightened operational scrutiny. Adding further legal pressure, the law firm Levi & Korsinsky filed a securities fraud class-action lawsuit against MEDP, alleging that the president oversaw misleading disclosures to investors.
Market Context and Trading Activity
MEDP entered earnings having already pulled back significantly from its 52-week high of $628.92. Pre-market volume on April 23 is heavily elevated, consistent with the pattern of sharp earnings-day reactions the stock has shown across recent quarters. Broader healthcare and CRO peers, including ICON and IQVIA (IQV), will be watched for any sympathy moves, as weak bookings data from Medpace could signal broader softness in the clinical trial outsourcing market. The selloff on elevated volume, combined with consecutive below-consensus book-to-bill readings, suggests that the market is repricing MEDP toward a lower growth multiple rather than treating this as a short-term noise event.
Trending AI Robots
For traders monitoring volatile earnings reactions like today's move in MEDP, Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing AI trading bots under current market conditions. Tickeron operates hundreds of AI bots spanning thousands of tickers, but only those demonstrating the most compelling real-time performance are featured in the Trending section. Each bot is distinct in the symbols it trades, its strategy type, its performance timeframe, and its risk parameters — from short-term mean-reversion plays to longer-horizon momentum approaches. Whether you're navigating a single-stock event or looking to systematize your broader market approach, the Trending AI Robots section offers a data-driven starting point worth exploring.
What Comes Next for MEDP
The most critical near-term data point for MEDP will be the Q2 2026 earnings release, expected in late July, which will confirm whether the sub-1.0x book-to-bill in Q1 was an isolated stumble or the beginning of a structural demand deceleration. Management's commentary on the pace of new business awards and project cancellations during the Q1 2026 earnings conference call — scheduled for April 23 at 9:00 a.m. ET — will be closely parsed for early signals. Analysts will also scrutinize the company's full-year revenue guidance range of $2.755–$2.855 billion, which straddles the consensus estimate of $2.81 billion, for any revised signals on bookings cadence. Progress on identifying a successor to President Geiger and any updates on the securities fraud class-action proceedings will remain key sentiment drivers for institutional investors in the months ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MEDP sees its Stochastic Oscillator ascending out of oversold territory
On July 20, 2026, the Stochastic Oscillator for MEDP moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 59 instances where the indicator left the oversold zone. In of the 59 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 23, 2026. You may want to consider a long position or call options on MEDP as a result. In of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MEDP just turned positive on July 23, 2026. Looking at past instances where MEDP's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MEDP advanced for three days, in of 320 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 256 cases where MEDP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for MEDP moved out of overbought territory on July 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MEDP broke above its upper Bollinger Band on July 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MEDP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (37.879) is normal, around the industry mean (13.281). P/E Ratio (34.636) is within average values for comparable stocks, (151.072). MEDP's Projected Growth (PEG Ratio) (3.156) is slightly higher than the industry average of (1.664). MEDP has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.008). P/S Ratio (6.109) is also within normal values, averaging (8.152).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company
Industry MedicalSpecialties
Advertisement